<DOC>
	<DOCNO>NCT02751034</DOCNO>
	<brief_summary>The purpose study compare efficacy safety study medical device , Neuramis® Deep Lidocaine control medical device , Restylane® PERLANE-L correction nasolabial fold</brief_summary>
	<brief_title>Efficacy Safety Evaluation Study Neuramis® Deep Lidocaine Correction Nasolabial Fold</brief_title>
	<detailed_description>This study multi-center , double blind , intra-individual control , active-controlled clinical trial . Efficacy Safety evaluate appointed time subject visit clinical site Injecting medical device .</detailed_description>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>1 . Male female age 30 70 year , inclusive 2 . Subjects want improvement bilateral nasolabial fold rat 3 4 point Wrinkle Severity Rating Scale 3 . Subjects visually symmetrical bilateral nasolabial fold 4 . Subjects consent abstain wrinkle improvement treatment low face ( low orbital rim ) trial 5 . Subjects capable understand follow instruction , participate entire course trial 6 . Subjects voluntarily decide participate trial provide write consent Informed Consent Form 1 . Subjects administer anticoagulant ( except lowdose aspirin ( 100mg , 300mg/day ) equivalent ) within 2 week prior screen 2 . Subjects facelift , soft tissue augmentation , medium deeper peeling , dermal photorejuvenation lower face ( low orbital rim ) wrinkle improvement within 6 month prior screen 3 . Subjects receive treatment calcium hydroxyapatite ( CaHA ) investigational medical device injection site within 1 year screen 4 . Subjects implanted permanent expander prosthesis investigational medical device injection site , softform silicon 5 . Subjects scar skin lesion investigational medical device injection site may interfere judgment treatment effect 6 . Subjects history anaphylaxis severe complicate allergy allergy lidocaine hyaluronic acid product 7 . Subjects history hypertrophic scar keloid 8 . Subjects skin disease wound infection investigational medical device injection site 9 . Subjects participate another clinical trial within 30 day prior screen 10 . Pregnant breastfeed woman woman childbearing potential use medically acceptable contraception consent practice birth control screen end trial 11 . Subjects otherwise determine investigator ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Wrinkle Severity Rating Scale</keyword>
	<keyword>Global Aesthetic Improvement Scale</keyword>
	<keyword>Hyaluronic acid filler</keyword>
	<keyword>filler</keyword>
	<keyword>Nasolabial Fold</keyword>
</DOC>